Press Releases

13 Dec 2017The Medicines Company to Host Investor Day on January 23, 201829 Nov 2017The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics15 Nov 2017The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors06 Nov 2017The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran25 Oct 2017The Medicines Company Reports Third-Quarter 2017 Business and Financial Results20 Oct 2017The Medicines Company to Announce Third-Quarter 2017 Financial Results on October 2505 Oct 2017The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 201728 Sep 2017The Medicines Company to Present Data at IDWeek 2017 on Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem and vaborbactam)30 Aug 2017The Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam)28 Aug 2017New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials09 Aug 2017The Medicines Company Reports Second Quarter 2017 Business and Financial Results31 Jul 2017The Medicines Company to Announce Second-Quarter 2017 Financial Results on August 925 Jul 2017The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE30 May 2017The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam04 May 2017The Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference26 Apr 2017The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran26 Apr 2017The Medicines Company Reports First-Quarter 2017 Financial Results17 Apr 2017The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam12 Apr 2017The Medicines Company to Announce First-Quarter 2017 Financial Results on April 26, 201731 Mar 2017The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors30 Mar 2017The Medicines Company to Present at Needham Healthcare Conference17 Mar 2017The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran14 Mar 2017The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.1706 Mar 2017The Medicines Company to Host Conference Call and Webcast at Upcoming American College of Cardiology’s 66th Annual Scientific Sessions28 Feb 2017The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results21 Feb 2017The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)17 Feb 2017The Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial Results on February 28, 201725 Jan 2017The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66th Annual Scientific Session08 Jan 2017The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)04 Jan 2017The Medicines Company to Present at J. P. Morgan Healthcare Conference

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com